Validación del método analítico para determinar magaldrato y simeticona en suspensión oral en el laboratorio-neofármaco

Abstract

This titling work was developed with the aim of validating the analytical method for determination of Magaldrate and Simethicone in Oral Suspension at the Neofármaco Laboratory. Cia Ltda., for which the principles of Magaldrate and Simethicone present in the form oral suspension pharmaceutical and the range of analytical methodology developed to establish optimal conditions for control in the finished product process at the start of the testing of the active substances in routine analysis. As for the methodology established in the development quantitative, applied, explanatory, experimental and cross-cutting was used. The population was including mainly semi-finished oral suspension in Neofármaco Cía. Ltda. Among the main results it was shown that for the pharmaceutical form of Oral Suspension the analysis was developed by discrepancy percentages for both Standard Magaldrate vs Placebo (Magaldrate plus excipients) 4.4233%, Magaldrate with active substances 1.4744% and Simethicone with placebo loaded 4,1899%, Simethicone with active substances 1,9130% Based on results obtained we can say that the percentages of discrepancy of the active ingredients are within the acceptance range, based on the specification stated above, as well as, it was determined that in relation to selectivity the percentage parameter was 4.4233% in the Magaldrate STD vs Placebo loaded and 1.4744% in Magaldrate STD vs Simethicone STD. herself established as a recommendation to establish follow-up protocols to investigations in line with raw materials that are implemented within the Neo-Pharmaceutical Laboratory under conditions external or internal investigations which must be stipulated within future investigations and additionally it is recommended that the university encourage this type of research that helps the development of the and help the well-being of the general population.